AstraZeneca Plans $200-Million Manufacturing Plant in China - - BioPharm International

ADVERTISEMENT

AstraZeneca Plans $200-Million Manufacturing Plant in China


BioPharm Bulletin

AstraZeneca is investing $200 million in a new manufacturing site in China Medical City (CMC), Taizhou, Jiangsu province, China. The new site represents AstraZeneca’s largest investment in a single manufacturing facility globally.

The site will produce intravenous and oral solid medicines for the company’s business in China. Construction of the site is scheduled to be complete at the end of 2013.

AstraZeneca first established a presence in China in 1993 and generated more than $1 billion in revenues in that country in 2010. AstraZeneca’s other facilities and project work in China include a manufacturing and supply site in Wuxi New District, Jiangsu Province; the AstraZeneca Innovation Center China, a translational science center; an established sales and marketing operation; large-scale clinical development capabilities; and a network of collaborations with academic and medical institutions.

AstraZeneca’s plans for its new manufacturing site in China follow recent investment in emerging markets. In June 2011, AstraZeneca unveiled plans to establish a Predictive Science Center in St. Petersburg, Russia. The center will be staffed with 30 employees and focus on developing bioinformatics, data-analysis methods, software, and systems to help predict the safety and efficacy of potential new medicines. Earlier this year, the company began constructing a $150-million manufacturing facility in the Kaluga region to supply locally manufactured medicines in Russia.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here